Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies.

Exp Hematol Oncol · 2023 · PMC10578030 · PMID 37845755

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

In a post hoc subgroup analysis of TN patients in the phase III, PHOENIX trial, a numerical trend was observed toward improved EFS and PFS with ibrutinib in combination with R‐CHOP when compared with R-CHOP alone in patients with high MYC/BCL2 co‐expression [ 89 ].

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.